Vigilent Labs (v.LABS)

Vigilent Labs has assembled a team of experts that bring a depth of expertise and knowledge in the diagnostic, medical and surveillance markets. With over 100 years of combined science, regulatory and government relations experience, Vigilent offers a single source for the spectrum of COVID-19 testing, including SARS-CoV-2 antibody, antigen, and molecular diagnostics. With current and new partnerships Vigilent Labs’vision is to offer communities a complete answer to the COVID-19 pandemic and future health events.

Addressable Markets

  • Healthcare Systems – Hospitals, Point Of Care, Acute Care Facilities, At Home
  • Government, General Services Administration, International Charities- Humanity Support
  • Commercial - Events, Factories, Travel Industry
  • Education Systems – Schools, Universities

Vigilent Labs Production Facilities

  • Headquarters in North Charleston, S.C.
  • Department of Health and Human Services, FDA Registration Number 10081264
  • 10,000 sq. ft., with a 40,000 Kit/daily production design with expansion potential
  • Vigilent Labs Manufacturing/Production capability is configured to produce product as a contract manufacturer for third party products
  • Vigilent Labs follows ISO 13485 - medical device manufacturers
  • Laramie WY, Sales and R&D
  • 18,800 sq.ft. facility, with room for production redundancy
  • Headquarters for Vigilent Labs Mobile CLIA Laboratories

Creating A Digital All Clear Pass: v.PASS

  • The v.LABS platform has the capability to utilize a digital QR Code that encrypts the results from a test. For example, in managing the highly contagious COVID-19, participants in public spaces may be required to show proof of a negative test result before entry.
  • The v.LABS Platform would screen the participant and create a digital “pass” for a negative test result, indicating the participant is ”COVID Clear”. The QR Code is widely utilized and easily adaptable via v.APP.
  • Digital time and date stamp with geo-tagging for precise situational awareness of the context for where data is collected for each test result.
  • Education Systems – Schools, Universities

The v.LABS Platform has been designed as a digital, hand-held, point-of-test, Lateral Flow Immuno-Assay (“LFIA”) identification and detection device.

  • A simple nasal swab is added to reagent and then three drops are put to on a test strip.
  • The reusable v.RESOLUTE READER, then gives accurate digital test results within 10 min.
  • Automated digitalization of the tests results enables tracking and monitoring
  • Through v.COP, command and control will enable on-site detection and triage.

Partnership Opportunities

  • Vigilent Labs’ goal is to provide best in class technologies and solutions.This is achieved through a focus on strategic partnerships of like-minded organizations
  • Vigilent Labs offers partners access to FDA/Regulatory experience and guidance, access to GSA contracts, international business opportunities, contract manufacturing, sales and marketing partnerships, RFP/Proposal response experience and access to Federal Organizations
  • Partnership opportunities include investment into Vigilent, cost sharing or RFP response